All In Biotech

Drug Trial Radar · NCT07606352

Safety and Efficacy of STL303 In Patients With Primary Immunoglobulin A (IgA) Nephropathy

A Multicenter, Randomised, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety and Efficacy of STL303 In Patients With Primary Immunoglobulin A (IgA) Nephropathy

Last checked: Nov 19, 2026Latest source record: Sep 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

15

Planned (sponsor's estimate)

Start

Aug 4, 2026

Primary completion

Jul 2027

Study completion Sep 2027

Sponsor

Lead sponsor
Sitala Bio LTDIndustry
Sponsor type
Industry
First posted
May 26, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, randomized, double-blind, placebo controlled Phase IIb study to explore the efficacy and safety of STL303 capsules in IgAN patients. About 15 patients dignosed with primary IgAN will be enrolled and randomized to three cohorts and take different dosage of STL303 or placebo capsules orally according to protocol.

Conditions

  • IgAN

Interventions

  • STL303Drug

    STL303 arm participants will receive a specific dose of STL303

  • STL303Drug

    STL303 arm participants will receive a specific dose of STL303

  • Placebo capsuleDrug

    Placebo arm participants will receive placebo capsules

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Treatment emergent adverse events (TEAEs), adverse events (AEs) and serious adverse events (SAEs)Time frame: Adverse events will be closely monitored, and participants will report to the clinic on Days 7, 14, 30, 45, 60, 90, 135 and at end of treatment on Day 180. On Day 210 an End of study safety follow up will also be conducted.

Locations

8 sites in 1 country. Site status is shown where the registry gives one.

  • John Hunter Hospital

    Newcastle, New South Wales, Australia · Recruiting

  • Nepean Hospital

    Penrith, New South Wales, Australia · Recruiting

  • Prince of Wales Hospital

    Sydney, New South Wales, Australia · Not yet recruiting

  • Concord Hospital

    Sydney, New South Wales, Australia · Recruiting

  • Research Site

    Woolloongabba, Queensland, Australia · Recruiting

  • Research Site

    Clayton, Victoria, Australia · Recruiting

  • Research Site

    Saint Albans, Victoria, Australia · Recruiting

  • Royal Perth Hospital

    Perth, Western Australia, Australia · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.